- Protein Name
- Cytoplasmic tyrosine-protein kinase BMX
- Gene Name
- BMX
- Organism
-
Homo sapiens
- Function
- Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen receptors and integrins. Induces tyrosine phosphorylation of BCAR1 in response to integrin regulation. Activation of BMX by integrins is mediated by PTK2/FAK1, a key mediator of integrin signaling events leading to the regulation of actin cytoskeleton and cell motility. Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis. Required for the phosphorylation and activation of STAT3, a transcription factor involved in cell differentiation. Also involved in interleukin-6 (IL6) induced differentiation. Plays also a role in programming adaptive cytoprotection against extracellular stress in different cell systems, salivary epithelial cells, brain endothelial cells, and dermal fibroblasts. May be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1. May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
19 |
2 |
8.5 |
| DFG |
16 |
10 |
11.5 |
| PIF |
16 |
9 |
15.0 |
| EDI |
13 |
11 |
12.0 |
| MT3 |
18 |
15 |
16.0 |
| AAS |
24 |
2 |
10.0 |
| LBP |
3 |
3 |
3.0 |
| ATP |
20 |
6 |
15.5 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
DFG site |
PIF site |
DRS site |
DEF site |
EDI site |
MT3 site |
AAS site |
LBP site |
CMP site |
PDIG site |
ATP site |
PMP site |
| Total Druggable Structures per Site |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
2 |
0 |
0 |
0 |
2 |
0 |
|
3SXR
|
11 |
11 |
16 |
0 |
0 |
13 |
18 |
24 |
3 |
0 |
0 |
16 |
0 |
|
3SXS
|
0 |
12 |
9 |
0 |
0 |
0 |
15 |
17 |
0 |
0 |
0 |
20 |
0 |
|
AFP51813
|
19 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |